Scientific Online Resource System

Annual for Hospital Pharmacy

Endometriosis - Review Of Current Therapeutic Aproaches For Disease Control

Victoria Spasova, Vesela Karamisheva, Rada Staneva, Savina Hadjidekova, Olga Antonova, Liliya Koleva, Draga Toncheva


Endometriosis is an estrogen-dependent chronic disease characterized by the presence of endometrial tissue outside the uterine cavity. Globally, it affects about 10% of women worldwide. It causes dysmenorrhea,chronic pelvic pain, dyspareunia, and infertility.
Medication treatment plays a key role in disease management. In most cases, medications should be combined with surgery in order to eradicate the disease. The medication treatment should be individualized considering the severity of endometriosis, efficacy of the drug, its side effects, patient`s preferences, age, and reproductive plans.
Nowadays, most of the drugs used to treat endometriosis aim to suppress ovarian function. The most widelyused and with the best therapeutic outcomes are the combined oral contraceptives, gonadotropin-releasing hormone agonists, and progestins. In addition to these well-established therapies, new horomonal and non-hormonal therapeutics that modulate various pathogenic pathways are available. We review currently availabletreatment options - the classical ones and the new therapies that are still not approved.


endometriosis, treatment, pain, infertilit

Full Text


Parasar P, Ozcan P, Terry KL. Endometriosis: Epidemiology, Diagnosis and Clinical Management. Curr Obstet Gynecol Rep. 2017;6(1):34-41.

Machairiotis N, Stylianaki A, Dryllis G, Zarogoulidis P, Kouroutou P, Tsiamis N, et al. Extrapelvic endometriosis: a rare entity or an under diagnosed condition? Diagn Pathol. 2013;8:194.

Morotti M, Vincent K, Becker CM. Mechanisms of pain in endometriosis. Eur J Obstet Gynecol Reprod Biol. 2017;209:8- 13.

Bulletti C, Coccia ME, Battistoni S, Borini A. Endometriosis and infertility. J Assist Reprod Genet. 2010;27(8):441-7.

Mettler L, Ruprai R, Alkatout I. Impact of medical and surgical treatment of endometriosis on the cure of endometriosis and pain. Biomed Res Int. 2014;2014:264653.

Tafi E, Leone Roberti Maggiore U, Alessandri F, Bogliolo S, Gardella B, Vellone VG, et al. Advances in pharmacotherapy for treating endometriosis. Expert Opin Pharmacother. 2015;16(16):2465-83.

Hughes E, Brown J, Collins JJ, Farquhar C, Fedorkow DM, Vanderkerckhove P. Ovulation suppression for endometriosis for women with subfertility. Cochrane Database Syst Rev. 2007(3).

Dunselman GA, Vermeulen N, Becker C, Calhaz-Jorge C, D`Hooghe T, De Bie B, et al. ESHRE guideline: management of women with endometriosis. Hum Reprod. 2014;29(3):400- 12.

Barra F, Scala C, Mais V, Guerriero S, Ferrero S. Investigational drugs for the treatment of endometriosis, an update on recent developments. Expert Opin Investig Drugs. 2018;27(5):445- 58.

Ferrero S, Evangelisti G, Barra F. Current and emerging treatment options for endometriosis. Expert Opin Pharmacother. 2018;19(10):1109-25.

Weisberg E, Fraser IS. Contraception and endometriosis: challenges, efficacy, and therapeutic importance. Open Access J Contracept. 2015;6:105-15.

Vercellini P, Barbara G, Somigliana E, Bianchi S, Abbiati A, Fedele L. Comparison of contraceptive ring and patch for the treatment of symptomatic endometriosis. Fertil Steril. 2010;93(7):2150-61.

Harada T, Momoeda M, Taketani Y, Hoshiai H, Terakawa N. Low-dose oral contraceptive pill for dysmenorrhea associated with endometriosis: a placebo-controlled, double-blind, randomized trial. Fertil Steril. 2008;90(5):1583-8.

Parazzini F, Di Cintio E, Chatenoud L, Moroni S, Ardovino I, Struzziero E, et al. Estroprogestin vs. gonadotrophin agonists plus estroprogestin in the treatment of endometriosis-related pelvic pain: a randomized trial. Eur J Obstet Gynecol Reprod Biol. 2000;88(1):11-4.

Guzick DS, Huang L-S, Broadman BA, Nealon M, Hornstein MD. Randomized trial of leuprolide versus continuous oral contraceptives in the treatment of endometriosis- associated pelvic pain. Fertil Steril. 2011;95(5):1568-73.

Vercellini P, Trespidi L, Colombo A, Vendola N, Marchini M, Crosignani PG. A gonadotropin-releasing hormone agonist versus a low-dose oral contraceptive for pelvic pain associated with endometriosis**This work was conducted within the framework of the Italian National Research Council Applied Project `Prevention and Control of Disease Factors,` subproject 5 (Fertility Control), Fertil Steril. 1993;60(1):75-9.

Cheewadhanaraks S, Choksuchat C, Dhanaworavibul K, Liabsuetrakul T. Postoperative Depot Medroxyprogesterone Acetate versus Continuous Oral Contraceptive Pills in the Treatment of Endometriosis-Associated Pain: A Randomized Comparative Trial. Gynecol Obstet Invest. 2012;74(2):151-6.

Vercellini P, Frontino G, De Giorgi O, Pietropaolo G, Pasin R, Crosignani PG. Continuous use of an oral contraceptive for endometriosis-associated recurrent dysmenorrhea that does not respond to a cyclic pill regimen. Fertil Steril. 2003;80(3):560-3.

Seracchioli R, Mabrouk M, Frascà C, Manuzzi L, Savelli L, Venturoli S. Long-term oral contraceptive pills and postoperative pain management after laparoscopic excision of ovarian endometrioma: a randomized controlled trial. Fertil Steril. 2010;94(2):464-71.

Seracchioli R, Mabrouk M, Frascà C, Manuzzi L, Montanari G, Keramyda A, et al. Long-term cyclic and continuous oral contraceptive therapy and endometrioma recurrence: a randomized controlled trial. Fertil Steril. 2010;93(1):52-6.

Klipping C, Duijkers I, Fortier MP, Marr J, Trummer D, Elliesen

J. Contraceptive efficacy and tolerability of ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen: an open- label, multicentre, randomised, controlled study. J Fam Plann Reprod Health Care. 2012;38(2):73-83.

Jensen JT, Garie SG, Trummer D, Elliesen Jr. Bleeding profile of a flexible extended regimen of ethinylestradiol/drospirenone in US women: an open-label, three-arm, active-controlled, multicenter study. Contraception. 2012;86(2):110-8.

Grandi G, Mueller M, Bersinger NA, Cagnacci A, Volpe A, McKinnon B. Does dienogest influence the inflammatory response of endometriotic cells? A systematic review. Inflammation Research. 2016;65(3):183-92.

Grandi G, Mueller MD, Papadia A, Kocbek V, Bersinger NA, Petraglia F, et al. Inflammation influences steroid hormone receptors targeted by progestins in endometrial stromal cells from women with endometriosis. J Reprod Immunol. 2016;117:30-8.

Berlanda N, Somigliana E, Viganò P, Vercellini P. Safety of medical treatments for endometriosis. Expert Opin Drug Saf. 2016;15(1):21-30.

Ailawadi RK, Jobanputra S, Kataria M, Gurates B, Bulun SE. Treatment of endometriosis and chronic pelvic pain with letrozole and norethindrone acetate: a pilot study. Fertil Steril. 2004;81(2):290-6.

Ferrero S, Camerini G, Seracchioli R, Ragni N, Venturini PL, Remorgida V. Letrozole combined with norethisterone acetate compared with norethisterone acetate alone in the treatment of pain symptoms caused by endometriosis. Hum Reprod. 2009;24(12):3033-41.

Vercellini P, Pietropaolo G, De Giorgi O, Pasin R, Chiodini A, Crosignani PG. Treatment of symptomatic rectovaginal endometriosis with an estrogen-progestogen combination versus low-dose norethindrone acetate. Fertil Steril 2005;84(5):1375-87.

Ferrero S, Camerini G, Ragni N, Venturini PL, Biscaldi E, Seracchioli R, et al. Letrozole and norethisterone acetate in colorectal endometriosis. Eur J Obstet Gynecol Reprod Biol. 2010;150(2):199-202.

Kaser DJ, Missmer SA, Berry KF, Laufer MR. Use of Norethindrone Acetate Alone for Postoperative Suppression of Endometriosis Symptoms. J Pediatr Adolesc Gynecol. 2012;25(2):105-8.

Bayoglu Tekin Y, Dilbaz B, Altinbas SK, Dilbaz S. Postoperative medical treatment of chronic pelvic pain related to severe endometriosis: levonorgestrel-releasing intrauterine system versus gonadotropin-releasing hormone analogue. Fertil Steril. 2011;95(2):492-6.

Tanmahasamut P, Rattanachaiyanont M, Angsuwathana S, Techatraisak K, Indhavivadhana S, Leerasiri P. Postoperative levonorgestrel-releasing intrauterine system for pelvic endometriosis-related pain: a randomized controlled trial. Obstet Gynecol. 2012;119(3):519-26.

Vercellini P, Frontino G, De Giorgi O, Aimi G, Zaina B, Crosignani PG. Comparison of a levonorgestrel-releasing intrauterine device versus expectant management after conservative surgery for symptomatic endometriosis: a pilot study. Fertil Steril. 2003;80(2):305-9.

34. Harada T, Taniguchi F. Dienogest: A New Therapeutic Agent for the Treatment of Endometriosis. Womens Health (Lond). 2010;6(1):27-35.

Andres MdP, Lopes LA, Baracat EC, Podgaec S. Dienogest in the treatment of endometriosis: systematic review. Arch Gynecol Obstet. 2015;292(3):523-9.

Morotti M, Sozzi F, Remorgida V, Venturini PL, Ferrero S. Dienogest in women with persistent endometriosis-related pelvic pain during norethisterone acetate treatment. Eur J Obstet Gynecol Reprod Biol. 2014;183:188-92.

Brown J, Kives S, Akhtar M. Progestagens and anti- progestagens for pain associated with endometriosis. Cochrane Database Syst Rev. 2012(3).

Abu Hashim H. Gonadotrophin-releasing hormone analogues and endometriosis: current strategies and new insights. Gynecological Endocrinology. 2012;28(4):314-21.

Crosignani PG, Luciano A, Ray A, Bergqvist A. Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain. Hum Reprod. 2005;21(1):248-56.

Harada T, Momoeda M, Taketani Y,Aso T, Fukunaga M, Hagino H, et al. Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis- a randomized, double-blind, multicenter, controlled trial. Fertil Steril. 2009;91(3):675-81.

Petta CA, Ferriani RA, Abrao MS, Hassan D, Rosa e Silva JC, Podgaec S, et al. Randomized clinical trial of a levonorgestrel- releasing intrauterine system and a depot GnRH analogue for the treatment of chronic pelvic pain in women with endometriosis. Hum Reprod. 2005;20(7):1993-8.

Brown J, Pan A, Hart RJ. Gonadotrophin-releasing hormone analogues for pain associated with endometriosis. Cochrane Database Syst Rev. 2010(12).

Crosignani P, Olive D, Bergqvist A, Luciano A. Advances in the management of endometriosis: an update for clinicians. Human Reproduction Update. 2005;12(2):179-89.

Vercellini P, Somigliana E, Viganò P, Abbiati A, Barbara G, Crosignani PG. Endometriosis: current therapies and new pharmacological developments. Drugs. 2009;69(6):649-75.

Fraser IS, Shearman RP, Jansen RP, Sutherland PD. A comparative treatment trial of endometriosis using the gonadotrophin-releasing hormone agonist, nafarelin, and the synthetic steroid, danazol. Aust N Z J Obstet Gynaecol. 1991;31(2):158-63.

Rotondi M, Labriola D, Rotondi M, Ammaturo FP, Amato G, Carella C, et al. Depot leuprorelin acetate versus danazol in the treatment of infertile women with symptomatic endometriosis. Eur J Gynaecol Oncol. 2002;23(6):523-6.

Brown J, Crawford TJ, Allen C, Hopewell S, Prentice

A. Nonsteroidal anti-inflammatory drugs for pain in women with endometriosis. Cochrane Database Syst Rev. 2017;1(1):Cd004753.

Cetel NS, Rivier J, Vale W, Yen SSC. The Dynamics of Gonadotropin Inhibition in Women Induced by an Antagonistic Analog of Gonadotropin-Releasing Hormone. The Journal of Clinical Endocrinology & Metabolism. 1983;57(1):62-5.

Finas D, Hornung D, Diedrich K, Schultze-Mosgau

A. Cetrorelix in the treatment of female infertility and endometriosis. Expert Opin Pharmacother. 2006;7(15):2155- 68.

Küpker W, Felberbaum RE, Krapp M, Schill T, Malik E, Diedrich K. Use of GnRH antagonists in the treatment of endometriosis. Reprod Biomed Online. 2002;5(1):12-6.

Diamond MP, Carr B, Dmowski WP, Koltun W, O`Brien C, Jiang P, et al. Elagolix Treatment for Endometriosis-Associated Pain: Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study. Reprod Sci. 2013;21(3):363-71.

Taylor HS, Giudice LC, Lessey BA, Abrao MS, Kotarski J, Archer DF, et al. Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist. NEJM. 2017;377(1):28-40.

Słopień R, Męczekalski B. Aromatase inhibitors in the treatment of endometriosis. Prz Menopauzalny. 2016;15(1):43- 7.

Ferrero S, Venturini PL, Ragni N, Camerini G, Remorgida

V. Pharmacological Treatment of Endometriosis. Drugs. 2009;69(8):943-52.

Amsterdam LL, Gentry W, Jobanputra S, Wolf M, Rubin SD, Bulun SE. Anastrazole and oral contraceptives: a novel treatment for endometriosis. Fertil Steril. 2005;84(2):300-4.

Ferrero S, Remorgida V, Venturini PL, Leone Roberti Maggiore U. Norethisterone acetate versus norethisterone acetate combined with letrozole for the treatment of ovarian endometriotic cysts: a patient preference study. Eur J Obstet Gynecol Reprod Biol. 2014;174:117-22.

Hefler LA, Grimm C, van Trotsenburg M, Nagele F. Role of the vaginally administered aromatase inhibitor anastrozole in women with rectovaginal endometriosis: a pilot study. Fertil Steril. 2005;84(4):1033-6.

Ferrero S, Biscaldi E, Luigi Venturini P, Remorgida V. Aromatase inhibitors in the treatment of bladder endometriosis. Gynecol Endocrinol. 2011;27(5):337-40.

Ferrero S, Venturini PL, Remorgida V. Changes in the size of rectovaginal endometriotic nodules infiltrating the rectum during hormonal therapies. Fertil Steril. 2010;94(4):S39.

Soysal S, Soysal ME, Ozer S, Gul N, Gezgin T. The effects of post-surgical administration of goserelin plus anastrozole compared to goserelin alone in patients with severe endometriosis: a prospective randomized trial. Hum Reprod. 2004;19(1):160-7.

Schultze-Mosgau M-H, Waellnitz K, Nave R, Klein S, Kraetzschmar J, Rautenberg T, et al. Pharmacokinetics, pharmacodynamics, safety and tolerability of an intravaginal ring releasing anastrozole and levonorgestrel in healthy premenopausal women: a Phase 1 randomized controlled trial. Hum Reprod. 2016;31(8):1713-22.

Reinecke I, Schultze-Mosgau MH, Nave R, Schmitz H, Ploeger BA. Model-Based Dose Selection for Intravaginal Ring Formulations Releasing Anastrozole and Levonorgestrel Intended for the Treatment of Endometriosis Symptoms. J Clin Pharmacol. 2017;57(5):640-51.

Ford MRW, Turner MJ, Wood C, Soutter WP. Endometriosis developing during tamoxifen therapy. American Journal of Obstetrics and Gynecology. 1988;158(5):1119.

Kulak J, Jr, Fischer C, Komm B, Taylor HS. Treatment with Bazedoxifene, a Selective Estrogen Receptor Modulator, Causes Regression of Endometriosis in a Mouse Model. Endocrinology. 2011;152(8):3226-32.

Sakr S, Naqvi H, Komm B, Taylor HS. Endometriosis Impairs Bone Marrow-Derived Stem Cell Recruitment to the Uterus Whereas Bazedoxifene Treatment Leads to Endometriosis Regression and Improved Uterine Stem Cell Engraftment. Endocrinology. 2014;155(4):1489-97.

Naqvi H, Sakr S, Presti T, Krikun G, Komm B, Taylor HS. Treatment with Bazedoxifene and Conjugated Estrogens Results in Regression of Endometriosis in a Murine Model1. Biol Reprod. 2014;90(6).

Yao Z, Shen X, Capodanno I, Donnelly M, Fenyk-Melody J, Hausamann J, et al. Validation of Rat Endometriosis Model by Using Raloxifene as a Positive Control for the Evaluation of Novel SERM Compounds. J Invest Surg. 2005;18(4):177-83.

Altintas D, Kokcu A, Kandemir B, Tosun M, Cetinkaya MB. Comparison of the effects of raloxifene and anastrozole on experimental endometriosis. Eur J Obstet Gynecol Reprod Biol. 2010;150(1):84-7.

Stratton P, Sinaii N, Segars J, Koziol D, Wesley R, Zimmer C, et al. Return of chronic pelvic pain from endometriosis after raloxifene treatment: a randomized controlled trial. Obstet Gynecol. 2008;111(1):88-96.

Carbonell JL, Riverón AM, Leonard Y, González J, Heredia B, Sánchez C. Mifepristone 2.5, 5, 10mg versus placebo in the treatment of endometriosis. Journal of Reproductive Health and Medicine. 2016;2(1):17-25.

Xue HL, Yu N, Wang J, Hao WJ, Li Y, Liu MY. Therapeutic effects of mifepristone combined with Gestrinone on patients with endometriosis. Pak J Med Sci. 2016;32(5):1268-72.

Chwalisz K, Perez MC, DeManno D, Winkel C, Schubert G, Elger W. Selective Progesterone Receptor Modulator Development and Use in the Treatment of Leiomyomata and Endometriosis. Endocr Rev. 2005;26(3):423-38.

Taylor HS, Osteen KG, Bruner-Tran KL, Lockwood CJ, Krikun G, Sokalska A, et al. Novel therapies targeting endometriosis. Reprod Sci. 2011;18(9):814-23.

Hull ML, Charnock-Jones DS, Chan CLK, Bruner-Tran KL, Osteen KG, Tom BDM, et al. Antiangiogenic Agents Are Effective Inhibitors of Endometriosis. J Clin Endocrinol Metab. 2003;88(6):2889-99.

Laschke MW, Menger MD. Basic mechanisms of vascularization in endometriosis and their clinical implications. Human Reproduction Update. 2018;24(2):207-24.

Park YH, Roh SY, Lee YC. Effect of sorafenib on experimental choroidal neovascularization in the rat. Clin Exp Ophthalmol. 2010;38(7):718-26.

Adnane L, Trail PA, Taylor I, Wilhelm SM. Sorafenib (BAY 43-9006, Nexavar®), a Dual-Action Inhibitor That Targets RAF/MEK/ERK Pathway in Tumor Cells and Tyrosine Kinases VEGFR/PDGFR in Tumor Vasculature. Methods in Enzymology. 407: Academic Press; 2006. p. 597-612.

Moggio A, Pittatore G, Cassoni P, Marchino GL, Revelli A, Bussolati B. Sorafenib inhibits growth, migration, and angiogenic potential of ectopic endometrial mesenchymal stem cells derived from patients with endometriosis. Fertil Steril. 2012;98(6):1521-30.e2.

Ozer H, Boztosun A, Açmaz G, Atılgan R, Akkar OB, Kosar MI. The Efficacy of Bevacizumab, Sorafenib, and Retinoic Acid on Rat Endometriosis Model. Reprod Sci. 2012;20(1):26- 32.

Ricci AG, Olivares CN, Bilotas MA, Meresman GF, Barañao RI. Effect of Vascular Endothelial Growth Factor Inhibition on Endometrial Implant Development in a Murine Model of Endometriosis. Reprod Sci. 2011;18(7):614-22.

Georgiev KD, Georgiev, DD, Georgiev, DS. New approach in the treatment of ophthalmic neovascular disorders: using fusion protein aflibercept. Biomedical Reviews. 2014:59-65.

Laschke MW, Elitzsch A, Scheuer C, Holstein JH, Vollmar B, Menger MD. Rapamycin induces regression of endometriotic lesions by inhibiting neovascularization and cell proliferation. Br J Pharmacol. 2006;149(2):137-44.

Hompes PG, Mijatovic V. Endometriosis: the way forward. Gynecol Endocrinol. 2007;23(1):5-12.

Agic A, Xu H, Finas D, Banz C, Diedrich K, Hornung D. Is Endometriosis Associated with Systemic Subclinical Inflammation? Gynecol Obstet Invest. 2006;62(3):139-47.

D`Antonio M, Martelli F, Peano S, Papoian R, Borrelli F. Ability of recombinant human TNF binding protein-1 (r- hTBP-1) to inhibit the development of experimentally-induced endometriosis in rats. J Reprod Immunol. 2000;48(2):81-98.

D`Hooghe TM, Cuneo S, Nugent N, Chai D, Deer F, Mwenda

J. Recombinant human TNF binding protein-1 (r-hTBP-1) inhibits the development of endometriosis in baboons: a prospective, randomized, placebo- and drug-controlled study. Fertil Steril. 2001;76(3):S1.

Richter ON, Dorn C, Rösing B, Flaskamp C, Ulrich U. Tumor necrosis factor alpha secretion by peritoneal macrophages in patients with endometriosis. Arch Gynecol Obstet. 2005;271(2):143-7.

Koninckx PR, Craessaerts M, Timmerman D, Cornillie F, Kennedy S. Anti-TNF-alpha treatment for deep endometriosis- associated pain: a randomized placebo-controlled trial. Hum Reprod. 2008;23(9):2017-23.

Huang H-Y, Chan S-H, Yu H-T, Wang H-S, Lai C-H, Soong Y-K. Interleukin-18 system messenger RNA and protein expression in human endometrium during the menstrual cycle. Fertil Steril. 2006;86(4):905-13.

Georgiev KD, Georgieva, MP. Pharmacological Properties of Monoclonal Antibodies Directed Against Interleukins.

Immunopathology and Immunomodulation. IntechOpen;2015; p. 261-86.

Elnashar A. Emerging treatment of endometriosis. Middle East Fertil Soc J. 2015;20(2):61-9.

Somigliana E, Viganò P, Rossi G, Carinelli S, Vignali M, Panina-Bordignon P. Endometrial ability to implant in ectopic sites can be prevented by interleukin-12 in a murine model of endometriosis. Hum Reprod. 1999;14(12):2944-50.

Sharma I, Dhawan V, Saha SC, Dhaliwal LK. In vitro effects of peroxisome proliferator-activated receptor-γ ligands on gene expression in lipopolysaccharide-induced endometrial and endometriotic stromal cells. Fertil Steril. 2011;95(2):829-31.e5.

Moravek MB, Ward EA, Lebovic DI. Thiazolidinediones as Therapy for Endometriosis: A Case Series. Gynecol Obstet

Invest. 2009;68(3):167-70.

Olivares C, Ricci A, Bilotas M, Barañao RI, Meresman G. The inhibitory effect of celecoxib and rosiglitazone on experimental endometriosis. Fertil Steril. 2011;96(2):428-33.

Rocha AL, Reis FM, Petraglia F. New trends for the medical treatment of endometriosis. Expert Opin Investig Drugs. 2012;21(7):905-19.

Dulak J, Jozkowicz A. Anti-angiogenic and anti-inflammatory effects of statins: relevance to anti-cancer therapy. Curr Cancer Drug Targets. 2005;5(8):579-94.

Bruner-Tran KL, Osteen KG, Duleba AJ. Simvastatin Protects against the Development of Endometriosis in a Nude Mouse Model. J Clin Endocrinol Metab. 2009;94(7):2489-94.

Yilmaz B, Ozat M, Kilic S, Gungor T, Aksoy Y, Lordlar N, et al. Atorvastatin causes regression of endometriotic implants in a rat model. Reproductive BioMedicine Online. 2010;20(2):291-9.

Pinar N, Soylu Karapinar O, Ozcan O, Ozgur T, Bayraktar S. Effect of alpha-lipoic acid on endometrial implants in an experimental rat model. Fundam Clin Pharmacol. 2017;31(5):506-12.

Bilska A, Wlodek L. Lipoic acid - the drug of the future? Pharmacol Rep. 2005;57(5):570-7.

Porpora MG, Brunelli R, Costa G, Imperiale L, Krasnowska EK, Lundeberg T, et al. A promise in the treatment of endometriosis: an observational cohort study on ovarian endometrioma reduction by N-acetylcysteine. Evid Based Complement Alternat Med. 2013;2013:240702.

Mmed ML, Liu X, Zhang Y, Guo S-W. Valproic Acid and Progestin Inhibit Lesion Growth and Reduce Hyperalgesia in Experimentally Induced Endometriosis in Rats. Reprod Sci. 2012;19(4):360-73.

Lindsay SF, Luciano DE, Luciano AA. Emerging therapy for endometriosis. Expert Opin Emerg Drugs. 2015;20(3):449-61.

Getov IN, Hristova TG, Lebanova HV, Grigorov EE. Study of obligations defined in agreements between parties involved in clinical trials of medicinal products in Bulgaria. Medicinski Glasnik. 2012;9(2):383-87.



Article Tools
Email this article (Login required)